'Chemo brain' lasts for months in many breast cancer survivors

January 11, 2017 by Kathleen Doheny, Healthday Reporter

(HealthDay)—"Chemo brain"—the mental fog common after breast cancer treatment—can persist for six months, new research shows.

The finding comes from one of the largest studies to date to look at chemotherapy-related thinking problems that plague many women treated for breast cancer. Those problems can include memory lapses, attention issues and difficulty processing information.

When researchers compared hundreds of U.S. women six months after chemotherapy ended with hundreds of healthy women, they found more than one-third of the chemotherapy group had a decline in thinking scores versus less than 15 percent of the others.

"The bottom line is, this is a real problem, are having difficulties and we need to acknowledge it is one of the difficulties of treatment," said Dr. Patricia Ganz.

Ganz is director of cancer prevention and control research at the University of California, Los Angeles Jonsson Comprehensive Cancer Center.

She's also co-author of an editorial accompanying the study, which was published recently in the Journal of Clinical Oncology.

Chemo brain can affect daily life in many ways, said study author Michelle Janelsins.

Patients say they make mistakes when writing down numbers, forget names of people they know, and don't remember the way to a familiar destination while en route, explained Janelsins. She's an assistant professor of surgery, radiation oncology and neuroscience at the University of Rochester Medical Center and the Wilmot Cancer Institute in New York.

The researchers aimed "to really assess the problem [of ] in a very methodical and comprehensive way by including a nationwide sample," Janelsins said.

Her team looked at 581 patients treated for breast cancer at multiple sites across the United States, comparing them with 364 healthy people without . The average age was 53.

The researchers analyzed patients' perceived impairment and also how others perceived the mental difficulties.

A month after chemo ended, 45 percent of patients reported a significant decline in so-called cognitive abilities, but only one in 10 in the comparison group did. The problems got better with time, but did not disappear.

After six months, 36 percent of patients still felt their mental ability had declined, compared to about 13 percent of the others.

Similar problems were experienced by women whether they received hormone therapy and/or radiation treatment after chemotherapy or chemo alone, the study found.

The researchers reported that younger women, black women and those with more anxiety and depression at the study start were more likely to have greater declines in brain functioning.

The researchers can't say why chemotherapy drugs seem to lead to the fuzzy thinking. Nor can they say there's a direct cause-and-effect relationship. They do know certain people are more vulnerable.

The important finding, Ganz said, is that some patients still had problems six months later.

While some researchers dismiss self-reporting as an untrustworthy research method, she disagreed. "If the patients tell you they are having [cognitive] difficulties, we have to acknowledge that and figure out a way to help," she noted.

"The good news is, there are large numbers of women who get better," Ganz said.

There may be biological reasons some patients are more prone to chemo brain, she said. She generally refers those who don't improve to a neuropsychologist. The focus then is on helping patients overcome the problems.

"There may be things we can do to organize their lives," Ganz said. Patients might begin to use planners or "sticky notes," she explained, to help remember things.

Exercise can also help, Janelsins said. In an earlier study, she found that patients who engaged in gentle yoga saw improvement in thinking function.

The study findings aren't a reason to change clinical practice at this point, Ganz and Janelsins agreed. What's needed, they said, is more information on which patients are most likely to develop the thinking problems.

Explore further: Chemo-brain among women with breast cancer is pervasive, study shows

More information: For more about chemo brain, visit the American Cancer Society.

Related Stories

Chemo-brain among women with breast cancer is pervasive, study shows

December 29, 2016
The largest study to date of a condition known as "chemo-brain" shows that women with breast cancer report it's a substantial problem after chemotherapy for as long as six months after treatment, according to investigators ...

Research suggests 'chemo brain' may involve neurophysiological change

April 19, 2013
(Medical Xpress)—For many years, breast cancer patients have reported experiencing difficulties with memory, concentration and other cognitive functions following cancer treatment. Whether this mental "fogginess" is psychosomatic ...

Mental training exercises shown to help mitigate the effects of 'chemo brain'

March 17, 2015
UCLA researchers have developed a program that could improve the day-to-day lives of women with breast cancer by addressing post-treatment cognitive difficulties, sometimes known as "chemo brain," which can affect up to 35 ...

Exercise as chemo-brain treatment

June 2, 2015
Cancer patients might feel their best if they simply maintain or only slightly increase their physical activity throughout chemotherapy instead of letting it decline, according to a University of Rochester scientist who presented ...

Memory problems after chemo linked to brain changes

May 29, 2014
(HealthDay News)—Breast cancer survivors who had chemotherapy show changes in brain activity during multitasking chores, according to a new Belgian study.

Breast cancer survivors struggle with cognitive problems several years after treatment

December 12, 2011
A new analysis has found that breast cancer survivors may experience problems with certain mental abilities several years after treatment, regardless of whether they were treated with chemotherapy plus radiation or radiation ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.